URBANI, GINEVRA
 Distribuzione geografica
Continente #
AS - Asia 92
EU - Europa 86
NA - Nord America 62
AF - Africa 2
Totale 242
Nazione #
US - Stati Uniti d'America 62
HK - Hong Kong 48
IT - Italia 46
SG - Singapore 33
IE - Irlanda 22
CN - Cina 7
DE - Germania 6
FI - Finlandia 5
KR - Corea 4
AT - Austria 3
CI - Costa d'Avorio 2
UA - Ucraina 2
EE - Estonia 1
NL - Olanda 1
Totale 242
Città #
Hong Kong 48
Singapore 25
Boardman 20
Dublin 20
Perugia 18
Chandler 12
Florence 4
Naples 4
Seoul 4
Lappeenranta 3
Los Angeles 3
Munich 3
Vienna 3
Abidjan 2
Bologna 2
Dallas 2
Helsinki 2
Irpin 2
Seattle 2
Ashburn 1
Boydton 1
Cascina 1
Frankfurt am Main 1
Liberty Lake 1
Philadelphia 1
Qingdao 1
Tallinn 1
Totale 187
Nome #
Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH 34
Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor Prognosis 34
Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma 32
Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma 30
Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling 24
Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease 20
Bile acids and bile acid activated receptors in the treatment of Covid-19 16
Immunology of bile acids regulated receptors 11
The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer 11
Bile acids serve as endogenous antagonists of the Leukemia inhibitory factor (LIF) receptor in oncogenesis 11
Activation of GPBAR1 attenuates vascular inflammation and atherosclerosis in a mouse model of NAFLD-related cardiovascular disease 11
Current Landscape and Evolving Therapies for Primary Biliary Cholangitis 8
Development of dual GPBAR1 agonist and RORγt inverse agonist for the treatment of inflammatory bowel diseases 6
Design, Synthesis, and Pharmacological Evaluation of Dual FXR-LIFR Modulators for the Treatment of Liver Fibrosis 5
Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments 5
Totale 258
Categoria #
all - tutte 1.779
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.779


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202384 4 1 0 4 10 12 0 4 46 0 0 3
2023/202493 2 2 2 2 10 2 20 12 19 4 11 7
2024/202581 6 29 20 25 1 0 0 0 0 0 0 0
Totale 258